NEW ORLEANS, L.A., March 19, 2019 – Myocardial Solutions’ MyoStrain® was featured in two different abstracts that were presented at the American College of Cardiology’s 68th Annual Scientific Session & Expo. The event was held in New Orleans, Louisiana on March 16th – 18th, 2019.
One abstract was based on a study completed at Sharon Regional Medical Center (Sharon, Pennsylvania) that used MyoStrain to quantify effects of obesity on the heart. The second abstract was presented by the German Heart Center Berlin (Berlin, Germany) who used MyoStrain to analyze the relationship between myocardial strain and myocardial damage as assessed by late gadolinium enhancement (LGE).
Links to the abstracts are provided below:
Citation: Kulifay S, et al. Detection and Evaluation of Subclinical Left Ventricular Dysfunction in Obese Patients Based on Global Longitudinal and Circumferential Strain. ACC 2019. (n=76)
Citation: Erley J, et al. Non-Contrast Cardiac Magnetic Resonance Based Detection of Myocardial Damage Using Myocardial Strain Analysis. ACC 2019.
About Myocardial Solutions, Inc.
Myocardial Solutions, Inc. (MSI) is a medical technology company working to transform the cardiac and cancer care continuum. Leveraging more than 400 publications in clinical research and development, MSI’s proprietary technology, MyoStrain®, is a 10-minute, non-invasive heart function test providing physicians with sensitive diagnostic markers to support the early assessment and individualized treatment of heart dysfunction. MyoStrain has received FDA-510(k) pre-market clearance, CE-mark certification, and is commercially available in the United States and Europe.
To learn more about MyoStrain, visit myocardialsolutions.com or connect with us on LinkedIn and Twitter @myocardialsoln.